Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria~* Has a foot infection as defined by the IDSA guidelines, with a severity rating of moderate or severe~* Either no current or recent (within 72 hours) antibiotic therapy for the DFI,~* Has documented adequate arterial perfusion in the affected limb (either palpable dorsalis pedis or posterior tibial pulses, or normal Doppler wave forms, or a toe blood pressure ≥ 45 mm Hg, or an ankle-brachial index (ABI) of \>0.6)~Exclusion Criteria:~* Proven or highly suspected, involvement of bone (i.e., osteomyelitis)~* More than one concurrent, infected, diabetic foot ulcer~* Hemoglobin A1c \> 11 on the day of presentation~* Requirement for ongoing immunosuppressive therapy (topical or inhaled corticosteroids are permitted)~* Serum creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST) or Alkaline Phosphatase \>2 times the upper limit of the normal range of the local testing laboratory~* Absolute neutrophil count \<1000~* Any condition that has required treatment with any other bismuth containing compound within the last 2 weeks (i.e., Kaopectate or Pepto-Bismol)~* Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months~* Need for any surgical therapy beyond debridement to treat the diabetic foot ulcer (e.g., incision and drainage, removal of necrotic tissue)~* Planned lower extremity amputation that will include their infected ulcer~* Known allergy to bismuth and/or MBN-101 excipients (methylcellulose, Tween 80 (polysorbate 80))~* Female patients who are pregnant, lactating, or who have a positive serum human chorionic gonadotropin (pregnancy) as determined by laboratory testing~* Immunocompromised due to illness or organ transplant~* History of any type of cancer (excluding non-melanoma localized skin cancer or completely excised and cured carcinoma-in-situ of uterine cervix)~* History of major medical noncompliance~* Other medical conditions which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MBN-101 (Type: EXPERIMENTAL): MBN-101: a suspension of 150, 375, or 600 microgram (µg)/milliliter (mL) (w:v) BisEDT drug particles in suspension in 3% methylcellulose / 0.5% polysorbate 80 / 10 millimole (mM) sodium chloride / 10 mM sodium phosphate.
- Vehicle (Type: PLACEBO_COMPARATOR): MBN-101 diluent (placebo): 3% methylcellulose / 0.5% polysorbate 80 / 10 mM sodium chloride / 10 mM sodium phosphate

Based on this trial design, predict the completion outcome and termination type (if applicable).